HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acrylamide

This article was originally published in The Rose Sheet

Executive Summary

Center for the Evaluation of Risks to Human Reproduction concludes there is "negligible concern" for adverse reproductive and developmental effects from exposure to acrylamide in the general population and there is "minimal concern" for acrylamide-induced heritable effects. There is "some concern" for adverse reproductive and developmental effects from occupational exposure to the chemical, the panel says. CERHR assessed the safety of acrylamide, an ingredient used in some cosmetics, during a meeting in May (1"The Rose Sheet" May 17, 2004, p. 9). The expert panel report from this evaluation will be available in about four weeks...

You may also be interested in...



CERHR Expert Panel To Review Acrylamide Safety

Human exposure to acrylamide through dermal contact with cosmetics and other consumer products is possible because the polyacrylamide used in these products may contain free acrylamide, the National Toxicology Program Center for the Evaluation of Risks to Human Reproduction states in a 1draft report on the chemical

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel